Studies on myeloproliferative neoplasms showed that AMPK activation could inhibit a series of JAK mutants, including JAK2V617F, and could thus effectively control antiproliferative effects and hemostatic dysfunction [38]. The gene discussed is PRKAA2; the disease is myeloproliferative neoplasm.